ificate of Mailing:

The undersigned certifies that this correspondence is being sent via First-Class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450, this 12th day of August, 2003.

Linda S. Evans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Darrow et al.

Atty Docket: ORT-1273

Serial No.:

09/607,745

Art Unit:

1652

Filed:

June 30, 2000

Examiner:

Sheridan Swope

For:

DNA Encoding Human Serine Protease D-G

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Statement is supplemental to the Information Disclosure Statements dated October 18, 2000, and January 2, 2002. This Statement is being filed under the provisions of 37 C.F.R. § 1.97(b)(3), i.e., before the mailing of a first Office Action on the merits.

Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 (or substitute form) citing references relating to the above-identified application. A copy of each reference listed on the enclosed form is enclosed. Each reference is in the English language. reference listed on the enclosed form was cited in a counterpart international patent application in a communication from the IPEA/US. A copy of the communication, namely, the PCT Written Opinion, is enclosed.

Applicant also directs the Examiner's attention to the discussion relating to Genbank Accession No. AF216312 at pages 47-53 of the specification.

This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that each cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the enclosed form to confirm consideration of each reference.

If any fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date August 12, 2003

Linda S. Evans Reg. No. 33,873

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933-7003 (858) 320-3406

PARTERIA	6 1 5 2	003	L						eet <u> </u>	of1
PATENT AND TRADEMARK OFFICE							ORT-1273	09/607	NO. RE	CENT
INFORMATION DISCLOSURE							APPLICANT Darrow et al.		AUI	SICIVEE
CITATION BY APPLICANT (Use several sheets if necessary)							FILING DATE June 30, 2000	09/607,745 RECEIVEL AUG 1 9 2003 GROUP AND WENTER 1600/2900		
				v-	_	U.S. PA	TENT DOCUMENTS	1.002		1000/2900
EXAMINER INITIAL	DOCUMENT NUMBER					DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
			+-							
		- -	+							
					1					
			-						··· - ·· -	
							·			
. <u></u>		<u> </u>	1		ـــــــــــــــــــــــــــــــــــــ	FOREIGN	PATENT DOCUMENTS	S		
	D	OCUM	ENT	NUME	BER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
- · · · · · · · · · ·								-		(uppou)
<u></u>			-	-						
<u> </u>			-				-			
•			+							
	THE	R DC	Cl	JME	NTS	(Includin	g Author, Title, Date,	Pertinent	Pages, E	tc.)
		serir	ne p	orote	ase (sion No. AF179224, Walli overexpressed in pancre			
		Data men	aba nbra	se G ane s	ENE	MBL Accesse e protease e	sion No. AF216312, Sme expressed in trachea, colo calization," 7 February 20	on and sma	I., "MT-SP2 all intestine	2, a novel type : identification,
,										
						-				
		<u> </u>				·	DATE CONSIDERED			
XAMINER							DATE CONCIDENCE			